Drug Profile
ASP 7398
Alternative Names: ASP7398Latest Information Update: 07 Feb 2018
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Nocturia
Most Recent Events
- 07 Feb 2018 Discontinued - Phase-I for Nocturia in Japan (PO) (Astellas Pharma pipeline, February 2018)
- 26 Feb 2016 Phase-I clinical trials in Nocturia in Japan (PO) prior to January 2016 (Astellas' pipeline, January 2016)